HR Execs on the Move

Columbia Laboratories

www.columbialabs.com

 
Columbia Laboratories is a specialty pharmaceutical company that develops and commercializes innovative products for women’s healthcare and endocrine-related conditions. Our FDA-approved products include formulations that treat infertility, menstrual irregularities and hormonal deficiencies. Columbia’s products utilize our proprietary Bioadhesive Delivery System (BDS), which leverages the principle of bioadhesion to administer medication. This technology can deliver many types of compounds, including hormones and peptides, providing numerous internal and licensing product development opportunities.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Alliance HealthCard, Inc.

Alliance HealthCard, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Smoky Lake - Family and Community Support Services

Smoky Lake - Family and Community Support Services is a Smoky Lake, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

The Assist Group

The Assist Group is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Lakewood, CO. To find more information about The Assist Group, please visit www.assistgroup.com

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.

NextGen

NextGen Healthcare is on a relentless quest to improve the lives of those who practice medicine and those they care for. We provide tailored solutions to fit the precise needs of ambulatory practices, as they strive to reach the quadruple aim while navigating the journey of value-based care. The result? Healthier patients and happier providers.